These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35115608)

  • 1. WIN site inhibition disrupts a subset of WDR5 function.
    Siladi AJ; Wang J; Florian AC; Thomas LR; Creighton JH; Matlock BK; Flaherty DK; Lorey SL; Howard GC; Fesik SW; Weissmiller AM; Liu Q; Tansey WP
    Sci Rep; 2022 Feb; 12(1):1848. PubMed ID: 35115608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Displacement of WDR5 from Chromatin by a WIN Site Inhibitor with Picomolar Affinity.
    Aho ER; Wang J; Gogliotti RD; Howard GC; Phan J; Acharya P; Macdonald JD; Cheng K; Lorey SL; Lu B; Wenzel S; Foshage AM; Alvarado J; Wang F; Shaw JG; Zhao B; Weissmiller AM; Thomas LR; Vakoc CR; Hall MD; Hiebert SW; Liu Q; Stauffer SR; Fesik SW; Tansey WP
    Cell Rep; 2019 Mar; 26(11):2916-2928.e13. PubMed ID: 30865883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and Structure-Based Optimization of Potent and Selective WD Repeat Domain 5 (WDR5) Inhibitors Containing a Dihydroisoquinolinone Bicyclic Core.
    Tian J; Teuscher KB; Aho ER; Alvarado JR; Mills JJ; Meyers KM; Gogliotti RD; Han C; Macdonald JD; Sai J; Shaw JG; Sensintaffar JL; Zhao B; Rietz TA; Thomas LR; Payne WG; Moore WJ; Stott GM; Kondo J; Inoue M; Coffey RJ; Tansey WP; Stauffer SR; Lee T; Fesik SW
    J Med Chem; 2020 Jan; 63(2):656-675. PubMed ID: 31858797
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of WIN site inhibitor on the WDR5 interactome.
    Guarnaccia AD; Rose KL; Wang J; Zhao B; Popay TM; Wang CE; Guerrazzi K; Hill S; Woodley CM; Hansen TJ; Lorey SL; Shaw JG; Payne WG; Weissmiller AM; Olejniczak ET; Fesik SW; Liu Q; Tansey WP
    Cell Rep; 2021 Jan; 34(3):108636. PubMed ID: 33472061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP1 interacts with WDR5 to enhance target gene recognition and facilitate tumorigenesis.
    Qin Y; Dong X; Lu M; Jing L; Chen Q; Guan F; Xiang Z; Huang J; Yang C; He X; Qu J; Yang Z
    Cancer Lett; 2024 Jul; 593():216952. PubMed ID: 38750719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribosome subunit attrition and activation of the p53-MDM4 axis dominate the response of MLL-rearranged cancer cells to WDR5 WIN site inhibition.
    Howard GC; Wang J; Rose KL; Jones C; Patel P; Tsui T; Florian AC; Vlach L; Lorey SL; Grieb BC; Smith BN; Slota MJ; Reynolds EM; Goswami S; Savona MR; Mason FM; Lee T; Fesik S; Liu Q; Tansey WP
    Elife; 2024 Apr; 12():. PubMed ID: 38682900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WDR5 is a conserved regulator of protein synthesis gene expression.
    Bryan AF; Wang J; Howard GC; Guarnaccia AD; Woodley CM; Aho ER; Rellinger EJ; Matlock BK; Flaherty DK; Lorey SL; Chung DH; Fesik SW; Liu Q; Weissmiller AM; Tansey WP
    Nucleic Acids Res; 2020 Apr; 48(6):2924-2941. PubMed ID: 31996893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting WDR5: A WINning Anti-Cancer Strategy?
    Aho ER; Weissmiller AM; Fesik SW; Tansey WP
    Epigenet Insights; 2019; 12():2516865719865282. PubMed ID: 31360909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-based discovery of potent WD repeat domain 5 inhibitors that demonstrate efficacy and safety in preclinical animal models.
    Teuscher KB; Chowdhury S; Meyers KM; Tian J; Sai J; Van Meveren M; South TM; Sensintaffar JL; Rietz TA; Goswami S; Wang J; Grieb BC; Lorey SL; Howard GC; Liu Q; Moore WJ; Stott GM; Tansey WP; Lee T; Fesik SW
    Proc Natl Acad Sci U S A; 2023 Jan; 120(1):e2211297120. PubMed ID: 36574664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
    Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
    J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of the multitasking high-affinity Win binding site of WDR5 in restricted and unrestricted conditions.
    Imran A; Moyer BS; Canning AJ; Kalina D; Duncan TM; Moody KJ; Wolfe AJ; Cosgrove MS; Movileanu L
    Biochem J; 2021 Jun; 478(11):2145-2161. PubMed ID: 34032265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural studies of WDR5 in complex with MBD3C WIN motif reveal a unique binding mode.
    Yang Y; Xu L; Zhang S; Yao L; Ding Y; Li W; Chen X
    J Biol Chem; 2024 Jul; 300(7):107468. PubMed ID: 38876301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
    Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
    Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders.
    Dölle A; Adhikari B; Krämer A; Weckesser J; Berner N; Berger LM; Diebold M; Szewczyk MM; Barsyte-Lovejoy D; Arrowsmith CH; Gebel J; Löhr F; Dötsch V; Eilers M; Heinzlmeir S; Kuster B; Sotriffer C; Wolf E; Knapp S
    J Med Chem; 2021 Aug; 64(15):10682-10710. PubMed ID: 33980013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. METTL3 orchestrates glycolysis by stabilizing the c-Myc/WDR5 complex in triple-negative breast cancer.
    Yuan XN; Shao YC; Guan XQ; Liu Q; Chu MF; Yang ZL; Li H; Zhao S; Tian YH; Zhang JW; Wei L
    Biochim Biophys Acta Mol Cell Res; 2024 Jun; 1871(5):119716. PubMed ID: 38547933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
    Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
    J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of Potent Small-Molecule Inhibitors of WDR5-MYC Interaction.
    Ding J; Li G; Liu H; Liu L; Lin Y; Gao J; Zhou G; Shen L; Zhao M; Yu Y; Guo W; Hommel U; Ottl J; Blank J; Aubin N; Wei Y; He H; Sage DR; Atadja PW; Li E; Jain RK; Tallarico JA; Canham SM; Chiang YL; Wang H
    ACS Chem Biol; 2023 Jan; 18(1):34-40. PubMed ID: 36594833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer.
    Kim JY; Banerjee T; Vinckevicius A; Luo Q; Parker JB; Baker MR; Radhakrishnan I; Wei JJ; Barish GD; Chakravarti D
    Mol Cell; 2014 May; 54(4):613-25. PubMed ID: 24793694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
    Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
    Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of Potent 2-Aryl-6,7-dihydro-5 H-pyrrolo[1,2- a]imidazoles as WDR5-WIN-Site Inhibitors Using Fragment-Based Methods and Structure-Based Design.
    Wang F; Jeon KO; Salovich JM; Macdonald JD; Alvarado J; Gogliotti RD; Phan J; Olejniczak ET; Sun Q; Wang S; Camper D; Yuh JP; Shaw JG; Sai J; Rossanese OW; Tansey WP; Stauffer SR; Fesik SW
    J Med Chem; 2018 Jul; 61(13):5623-5642. PubMed ID: 29889518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.